Stoke Therapeutics宣布首位患者接受STK-002一期临床研究给药,该药物有望成为治疗常染色体显性遗传性视神经萎缩(ADOA)的疾病修正疗法

美股速递
Feb 11

生物技术公司Stoke Therapeutics, Inc.宣布,其在研药物STK-002的一期临床研究已完成对首位患者的给药。STK-002被开发为一种潜在的疾病修正疗法,旨在治疗常染色体显性遗传性视神经萎缩(ADOA)。该阶段的研究将评估STK-002的安全性、耐受性及药代动力学特性。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10